达托霉素对北美近期分离的肺炎链球菌的活性。
Activity of daptomycin against recent North American isolates of Streptococcus pneumoniae.
作者信息
Restrepo M I, Velez J A, McElmeel M L, Whitney C G, Jorgensen J H
机构信息
Department of Medicine, University of Texas Health Science Center, San Antonio, Texas 78229, USA.
出版信息
Antimicrob Agents Chemother. 2003 Sep;47(9):2974-7. doi: 10.1128/AAC.47.9.2974-2977.2003.
Abstract
Daptomycin MICs at which 50% of isolates were inhibited (MIC(50)s) and MIC(90)s determined by the NCCLS broth microdilution method were both 0.25 microg/ml (range, 0.06 to 2 microg/ml) for 350 pneumococcal isolates. MICs determined by E test strips on commercially prepared Mueller-Hinton sheep blood agars with different calcium contents were 2 to 3 dilutions higher than those determined by strips that contained daptomycin plus calcium. Daptomycin zone diameters varied little on the same media.
摘要
采用美国国家临床实验室标准化委员会（NCCLS）肉汤微量稀释法测定的350株肺炎球菌分离株的50%被抑制时的达托霉素最低抑菌浓度（MIC50）和MIC90均为0.25μg/ml（范围为0.06至2μg/ml）。在不同钙含量的商业制备的穆勒-欣顿绵羊血琼脂上，用E试验条测定的MIC比含有达托霉素加钙的试验条测定的结果高2至3个稀释度。在相同培养基上，达托霉素抑菌圈直径变化不大。
相似文献
1
Activity of daptomycin against recent North American isolates of Streptococcus pneumoniae.达托霉素对北美近期分离的肺炎链球菌的活性。
Antimicrob Agents Chemother. 2003 Sep;47(9):2974-7. doi: 10.1128/AAC.47.9.2974-2977.2003.
2
In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers.达托霉素对来自11个北美医疗中心的2789株临床分离株的体外活性。
Antimicrob Agents Chemother. 2001 Jun;45(6):1919-22. doi: 10.1128/AAC.45.6.1919-1922.2001.
3
In vitro activity of daptomycin against vancomycin-resistant enterococci of various Van types and comparison of susceptibility testing methods.达托霉素对不同Van型耐万古霉素肠球菌的体外活性及药敏试验方法比较。
Antimicrob Agents Chemother. 2003 Dec;47(12):3760-3. doi: 10.1128/AAC.47.12.3760-3763.2003.
4
Activity of the Diaminopyrimidine AR-709 against recently collected multidrug-resistant isolates of invasive Streptococcus pneumoniae from North America.二氨基嘧啶AR-709对近期从北美收集的侵袭性肺炎链球菌多重耐药菌株的活性。
Antimicrob Agents Chemother. 2008 Mar;52(3):1147-9. doi: 10.1128/AAC.01387-07. Epub 2008 Jan 7.
5
Comparison of daptomycin Etest MICs on Mueller Hinton, IsoSensitest and brain heart infusion agars from Europe against 20 Staphylococcus aureus isolates.比较欧洲莫努匹拉韦 Etest MIC 值在 Mueller Hinton、IsoSensitest 和脑心浸液琼脂上对 20 株金黄色葡萄球菌分离株的结果。
Eur J Clin Microbiol Infect Dis. 2010 Oct;29(10):1261-4. doi: 10.1007/s10096-010-0996-x. Epub 2010 Jun 22.
6
Postantibiotic effects of daptomycin against 14 staphylococcal and pneumococcal clinical isolates.达托霉素对14株葡萄球菌和肺炎球菌临床分离株的抗生素后效应
Antimicrob Agents Chemother. 2003 Sep;47(9):3012-4. doi: 10.1128/AAC.47.9.3012-3014.2003.
7
Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests.达托霉素药敏试验：解释标准、质量控制及钙对体外试验的影响
Diagn Microbiol Infect Dis. 2000 Sep;38(1):51-8. doi: 10.1016/s0732-8893(00)00164-4.
8
Comparison of daptomycin MIC results by DIN, NCCLS, SFM, and SRGA methods for 297 Gram-positive organisms.采用DIN、NCCLS、SFM和SRGA方法对297株革兰氏阳性菌进行达托霉素最低抑菌浓度（MIC）结果比较。
Int J Antimicrob Agents. 2004 Jan;23(1):17-24. doi: 10.1016/j.ijantimicag.2003.06.002.
9
Determination of the pharmacodynamic profile of daptomycin against Streptococcus pneumoniae isolates with varying susceptibility to penicillin in a murine thigh infection model.在小鼠大腿感染模型中测定达托霉素对不同青霉素敏感性的肺炎链球菌分离株的药效学特征。
Chemotherapy. 2004 Apr;50(1):11-6. doi: 10.1159/000077278.
10
The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates.达托霉素对514株革兰氏阳性需氧临床分离株的体外活性。
J Antimicrob Chemother. 2001 Aug;48(2):219-23. doi: 10.1093/jac/48.2.219.
本文引用的文献
1
In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates.达托霉素、万古霉素、奎奴普丁-达福普汀、利奈唑胺及其他五种抗菌药物对307株革兰氏阳性厌氧菌和31株棒状杆菌临床分离株的体外活性。
Antimicrob Agents Chemother. 2003 Jan;47(1):337-41. doi: 10.1128/AAC.47.1.337-341.2003.
2
In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens.替加环素（GAR-936）、达托霉素及其他对照抗菌药物对糖肽类中介金黄色葡萄球菌及其他耐药革兰氏阳性病原体的体外和体内活性。
Antimicrob Agents Chemother. 2002 Aug;46(8):2595-601. doi: 10.1128/AAC.46.8.2595-2601.2002.
3
Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.对左氧氟沙星的耐药性与肺炎球菌肺炎治疗失败
N Engl J Med. 2002 Mar 7;346(10):747-50. doi: 10.1056/NEJMoa012122.
4
Macrolide resistance among invasive Streptococcus pneumoniae isolates.侵袭性肺炎链球菌分离株中的大环内酯类耐药性
JAMA. 2001 Oct 17;286(15):1857-62. doi: 10.1001/jama.286.15.1857.
5
Evaluation of daptomycin susceptibility testing by Etest and the effect of different batches of media.
J Antimicrob Chemother. 2001 Oct;48(4):557-61. doi: 10.1093/jac/48.4.557.
6
In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers.达托霉素对来自11个北美医疗中心的2789株临床分离株的体外活性。
Antimicrob Agents Chemother. 2001 Jun;45(6):1919-22. doi: 10.1128/AAC.45.6.1919-1922.2001.
7
Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis.美国对肺炎链球菌耐药性进行年度监测的必要性：两年纵向分析
Antimicrob Agents Chemother. 2001 Apr;45(4):1037-42. doi: 10.1128/AAC.45.4.1037-1042.2001.
8
Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study.获得左氧氟沙星耐药肺炎链球菌的危险因素：一项病例对照研究。
Clin Infect Dis. 2001 Mar 1;32(5):701-7. doi: 10.1086/319222. Epub 2001 Feb 28.
9
Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States.美国多重耐药肺炎链球菌的患病率不断上升。
N Engl J Med. 2000 Dec 28;343(26):1917-24. doi: 10.1056/NEJM200012283432603.
10
Comparative In vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens.达托霉素和万古霉素对耐药革兰氏阳性病原体的体外活性比较
Antimicrob Agents Chemother. 2000 Dec;44(12):3447-50. doi: 10.1128/AAC.44.12.3447-3450.2000.
Zotero 插件